Hanmi Flu outnumbers Tamiflu in flu medicine market
The market share of ‘Hanmi Flu,’ a Korean influenza treatment, exceeded 50%.
According to Hanmi Pharm on the 21st, after the flu watch was alerted, its prescriptions were rapidly increased, which made the market share 54.9% in the first week of December and outnumbered the market share of Tamifl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
